Screener / SEC EDGAR /CIK 0001711279 /10-K filed Feb 17, 2026, compared with Feb 19, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Krystal Biotech, Inc. KRYS

Compare with peers Embed
FY2025 at a glance

Sales up 33.9%, free cash flow up to $188.9M

XBRL, from each 10-K
RevenueStatements
$389.1M from $290.5M in FY2024
FY2016FY2025
Net incomeStatements
$204.8M from $89.2M in FY2024
FY2016FY2025
Free cash flowStatements
$188.9M from $119.2M in FY2024
FY2016FY2025
EPS (diluted)Statements
$6.84 from $3.00 in FY2024
FY2016FY2025
Operating marginStatements
41.5% from 22.6% in FY2024
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (33)
EPS (ttm)
7.36
Sales (ttm)
470.0M
Net income (ttm)
225.2M
Sales growth
+33.9%
EPS growth
+128%
Sales Q/Q
+30.2%
Free cash flow
310.1M
Gross margin
-
Oper. margin
48.4%
Net margin
47.9%
FCF margin
66.0%
R&D / sales
14.9%
Dividend
-
Debt/Eq
-
Curr. ratio
7.89
Cash
462.8M
Op. cash flow (ttm)
323.9M
EBITDA
167.0M
EBITDA margin
42.9%
Quick ratio
7.61
ROIC
12.1%
FCF after stock pay
134.4M
Tax rate
-8.1%
Stock pay / sales
14.0%
Shares out.
29.6M
Shares Y/Y
+0.7%
Book / share
48.44
Cash / share
15.62
Sales / share
15.86
Asset turnover
0.30
Days sales out.
120

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2021 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 389.1M Net income 204.8M
FY2021 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001711279-24-000005 FY2021 net income -69.6M · NetIncomeLoss, 0001711279-24-000005 0 FY2021 FY2022 revenue 0 · RevenueFromContractWithCustomerExcludingAssessedTax, 0001711279-25-000008 FY2022 net income -140.0M · NetIncomeLoss, 0001711279-25-000008 0 FY2022 FY2023 revenue 50.7M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001711279-26-000016 FY2023 net income 10.9M · NetIncomeLoss, 0001711279-26-000016 50.7M FY2023 FY2024 revenue 290.5M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001711279-26-000016 FY2024 net income 89.2M · NetIncomeLoss, 0001711279-26-000016 290.5M FY2024 FY2025 revenue 389.1M · RevenueFromContractWithCustomerExcludingAssessedTax, 0001711279-26-000016 FY2025 net income 204.8M · NetIncomeLoss, 0001711279-26-000016 389.1M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing.

Growth per share, FY2016 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +21.2% a year FY2020 $15.55 to FY2025 $40.72, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 $6.84$40.72$6.31
Dec 31, 2024 $3.00$31.82$4.01
Dec 31, 2023 $0.39$28.06-$3.63
Dec 31, 2022 -$5.49$20.49-$6.02
Dec 31, 2021 -$3.13$26.74-$5.24
Dec 31, 2020 -$1.71$15.55-$2.18
Dec 31, 2019 ---
Dec 31, 2018 ---
Dec 31, 2017 ---
Dec 31, 2016 ---

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $1.0B
  • − All liabilities $114.2M
  • = Net current asset value $910.4M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $1.2B
  • = Tangible book value $1.2B
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

KRYS against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Sales growth
+4.8%+20.2%
+33.9%25th of 155 · median +10.5%
Net margin
-4.1%15.3%
47.9%3rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
15.7%45th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
66.0%1st of 145 · median 10.0%
KRYS and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
KRYS Krystal Biotech, Inc.$470.0M +33.9%-47.9%15.7%66.0%-
PTGX Protagonist Therapeutics, Inc$551.7M -89.4%-62.0%31.5%19.8%-
ADMA Adma Biologics, Inc.$519.2M +19.6%68.5%35.1%41.6%25.6%0.45
WGS GeneDx Holdings Corp.$460.8M +40.0%68.7%-24.1%-45.4%-22.0%0.61
ZLAB Zai Lab Ltd$441.7M +15.3%53.4%-44.9%-35.2%-37.0%0.45
TWST Twist Bioscience Corp$431.8M +20.3%52.0%-31.7%-30.7%-21.6%-
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2023 · 10-K XBRL, year-end balances

Return on equity 16.8% FY2023: 1.4% net income ÷ equity
Net margin 52.6% FY2023: 21.6% profit per $ of sales: 204.8M ÷ 389.1M
Asset turnover 0.29× FY2023: 0.06× sales per $ of assets: 389.1M ÷ 1.3B
Leverage 1.09× FY2023: 1.05× assets per $ of equity: 1.3B ÷ 1.2B

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin above the peer median
    47.9% vs 6.8%
  • Return on equity above 15%
    15.7%
  • A profit in 3 of 5 years
Net margin, FY2021 to FY2025: 21.6% to 52.6%

Cash and shareholders

  • Free cash flow positive in 2 of 5 years
    $188.9M last year
  • Share count up over 4 years
    +34.9%
  • Cash from operations below net income
    $200.9M vs $204.8M
Free cash flow, FY2021 to FY2025: -116.3M to 188.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

KRYS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue389.1M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: -FY2021: 0FY2022: 0FY2023: 50.7MFY2024: 290.5MFY2025: 389.1M FY2017FY2019FY2021FY2023FY2025
Net income204.8M
FY2016: -1.1MFY2017: -7.9MFY2018: -10.9MFY2019: -19.1MFY2020: -32.2MFY2021: -69.6MFY2022: -140.0MFY2023: 10.9MFY2024: 89.2MFY2025: 204.8M FY2017FY2019FY2021FY2023FY2025
Free cash flow188.9M
FY2016: -1.3MFY2017: -4.1MFY2018: -11.7MFY2019: -25.1MFY2020: -40.9MFY2021: -116.3MFY2022: -153.5MFY2023: -100.6MFY2024: 119.2MFY2025: 188.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay134.4M
FY2016: -1.4MFY2017: -4.3MFY2018: -12.5MFY2019: -26.3MFY2020: -44.2MFY2021: -131.6MFY2022: -186.8MFY2023: -140.5MFY2024: 70.1MFY2025: 134.4M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)6.84
FY2016: -1.31FY2017: -1.48FY2018: -0.97FY2019: -1.20FY2020: -1.71FY2021: -3.13FY2022: -5.49FY2023: 0.39FY2024: 3.00FY2025: 6.84 FY2017FY2019FY2021FY2023FY2025
Diluted shares30.0M
FY2016: -FY2017: -FY2018: -FY2019: -FY2020: 18.8MFY2021: 22.2MFY2022: 25.5MFY2023: 27.8MFY2024: 29.7MFY2025: 30.0M FY2017FY2019FY2021FY2023FY2025

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue-----0050.7M290.5M389.1M
R&D741K3.2M7.8M15.6M17.9M27.9M42.5M46.4M53.6M58.0M
SG&A402K1.6M4.2M6.5M15.1M40.4M77.7M98.3M113.6M146.7M
Operating income-1.1M-4.8M-11.9M-22.1M-33.0M-68.3M-145.2M-109.6M65.7M161.3M
Interest expense----01.5M00--
Pretax income------69.6M-140.0M12.9M95.4M189.5M
Income tax-0000002.0M6.2M-15.4M
Net income-1.1M-7.9M-10.9M-19.1M-32.2M-69.6M-140.0M10.9M89.2M204.8M
EPS (diluted)-1.31-1.48-0.97-1.20-1.71-3.13-5.490.393.006.84
Diluted shares----18.8M22.2M25.5M27.8M29.7M30.0M
Depreciation & amortization2K23K141K1.1M1.9M2.8M4.1M5.0M6.0M5.7M
EBITDA-1.1M-4.7M-11.8M-21.0M-31.1M-65.5M-141.1M-104.6M71.7M167.0M
Operating margin--------216.2%22.6%41.5%
Net margin-------21.6%30.7%52.6%
Revenue growth--------+473%+33.9%
EPS growth--------+669%+128%

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-1.3M-3.9M-9.4M-18.7M-26.1M-47.9M-100.6M-88.8M123.4M200.9M
Capital spending15K210K2.2M6.4M14.8M68.3M53.0M11.8M4.2M12.0M
Free cash flow-1.3M-4.1M-11.7M-25.1M-40.9M-116.3M-153.5M-100.6M119.2M188.9M
Stock-based pay (added back)33K246K792K1.2M3.3M15.3M33.2M39.9M49.1M54.5M
Free cash flow after stock pay-1.4M-4.3M-12.5M-26.3M-44.2M-131.6M-186.8M-140.5M70.1M134.4M
Investing cash flow-15K-210K-10.3M-5.0M-11.2M-226.8M-114.1M82.6M-163.4M-58.4M
Financing cash flow3.2M51.8M73.8M107.5M118.0M347.7M35.3M202.8M27.0M8.7M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)33K246K792K1.2M3.3M15.3M33.2M39.9M49.1M54.5M
Stock-based pay / revenue-------78.8%16.9%14.0%
Operating lease cost----767K1.3M1.5M1.6M1.2M1.6M
Right-of-use assets--1.1M2.7M3.3M7.2M8.0M7.0M6.3M7.2M
Operating lease liabilities--1.4M3.3M3.9M8.0M8.9M8.1M7.3M9.3M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.